The team presents encouraging findings from patients with advanced solid tumors in their first clinical trial using a next-generation antibody.

Published Date: 05 Jun 2024

Initial findings from the bispecific antibody FS222's first phase 1 trial show that it is a medication with a tolerable safety profile and promising antitumor activity, particularly in individuals with metastatic cutaneous disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot